Navigation Links
Trubion Announces Presentation of Positive TRU-016 Data at ASCO
Date:6/2/2008

of B-cell malignancies," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "TRU-016 represents a first-in-class product opportunity with an exciting, differentiated pre-clinical profile. The demonstrated ability of TRU-016 to kill tumor cells through powerful apoptotic signaling as well as potent ADCC-mediated activity, combined with its synergy with chemotherapies and anti-CD20 therapies, adds to our confidence that this drug, either alone or in combination with other effective therapies, may offer meaningful benefits to patients with these diseases. We look forward to the results of our ongoing Phase 1/2 clinical trial currently evaluating TRU-016 in CLL patients."

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
2. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
5. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
6. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
7. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
8. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/25/2014)... N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... clinic, GPM Pediatrics, reacts to a recent study, which ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... exposed to severe stress are more likely than others to ... months before pregnancy." There were two specific types ...
(Date:7/24/2014)... July 24, 2014  Parnell Pharmaceuticals Holdings Ltd ... will be added to Parnell,s already extensive pipeline ... Ltd, a biotechnology company. The compounds now known ... promise in bone regeneration and dermal regeneration, respectively. ... compounds for the veterinary market with the potential ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Progress ... ushered in a new era of promising brain tumor ... Harvard Medical School, director of the Center for Neuro-Oncology, ... Association (ABTA) annual Patient and Family Conference in Chicago, ... how science and new technology are impacting the development ...
(Date:7/25/2014)... According to the new report "Sapphire ... and Geography - Analysis & Forecast to 2013 - ... to reach $3.01 Billion by 2020 at a CAGR ... devices is expected to reach $6.17 billion by 2020 ... analysis of application and geography. , Browse more than ...
(Date:7/25/2014)... Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and Splashtop ... Market, and will leverage the MaaS360 WorkPlace SDK ... data. , Splashtop Business and Splashtop Enterprise offer secure ... any device. High performance, ease of use, ...
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Garth Brooks ... performance at the Allstate Arena in Rosemont. Garth Brooks was ... time he released his first single in 1989. Since "Much Too ... flocked to the shows from the Tulsa, Okl. native and in ... wanted to see him back on a stage and in the ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3
... Artery-opening procedure can be done up to 21 hours later ... (HealthDay News) -- Many people who arrive at hospital emergency ... hours for artery-opening angioplasty, even if an electrocardiogram (EKG) shows ... , There was no significant difference in key measures of ...
... , , CARDIFF, Calif., Sept. 1 ... ( http://www.jedimindinc.com ) announced today that their Medical ... for patients in wheelchairs. An estimated 1.6 million Americans residing ... National Health Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical ...
... , , ATLANTA, Sept. 1 ... 50 schools across the U.S. with $2,000 ... ING Run For Something Better School Awards Program, financial ... for Sport and Physical Education (NASPE), is helping to ...
... Less invasive procedure shaves off lesions, researchers say , ... the esophagus can be treated effectively by less invasive, ... This is good news, as esophageal cancer arising from ... other cancer in the United States, and 90 percent ...
... Angeles, London, New Delhi, Singapore and Washington DC (1 ... and professional publisher is delighted to announce a new ... their official journal, Cephalalgia . Now in ... forum for original research papers, review articles and short ...
... available in French . , Montreal, ... autoimmune disorders which cause muscular inflammation are at increased ... Montreal researchers. Dr. Christian A. Pineau and his team ... Centre (RI-MUHC) have linked muscular inflammation to increased cardiovascular ...
Cached Medicine News:Health News:Sometimes Angioplasty Can Wait 2Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 2Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 3Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 4Health News:ING Awards $100,000 in Grants to Combat Childhood Obesity 5Health News:New Therapy Spares Organ in Early Esophageal Cancer 2Health News:SAGE to publish leading international headache journal Cephalalgia 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... Keeler ophthalmoscopes are individually adjusted for ... the eye, not on paper. This, along ... infinity focus, ensures that whatever the patient's ... and largest field of view. Lithium-ion technology ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: